The 36-month beta value for TXG is also noteworthy at 1.83. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 9 rating it as “hold,” and 1 rating it as “sell.”
The public float for TXG is 99.61M, and at present, short sellers hold a 7.47% of that float. The average trading volume of TXG on October 23, 2024 was 1.84M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TXG) stock’s latest price update
The stock of 10x Genomics Inc (NASDAQ: TXG) has decreased by -1.50 when compared to last closing price of 15.37.Despite this, the company has seen a loss of -4.84% in its stock price over the last five trading days. zacks.com reported 2024-10-22 that 10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TXG’s Market Performance
TXG’s stock has fallen by -4.84% in the past week, with a monthly drop of -31.83% and a quarterly drop of -20.19%. The volatility ratio for the week is 4.78% while the volatility levels for the last 30 days are 5.60% for 10x Genomics Inc. The simple moving average for the past 20 days is -18.44% for TXG’s stock, with a -47.13% simple moving average for the past 200 days.
Analysts’ Opinion of TXG
Many brokerage firms have already submitted their reports for TXG stocks, with Leerink Partners repeating the rating for TXG by listing it as a “Outperform.” The predicted price for TXG in the upcoming period, according to Leerink Partners is $35 based on the research report published on September 03, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see TXG reach a price target of $24. The rating they have provided for TXG stocks is “Buy” according to the report published on July 22nd, 2024.
JP Morgan gave a rating of “Neutral” to TXG, setting the target price at $20 in the report published on July 18th of the current year.
TXG Trading at -27.34% from the 50-Day Moving Average
After a stumble in the market that brought TXG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.85% of loss for the given period.
Volatility was left at 5.60%, however, over the last 30 days, the volatility rate increased by 4.78%, as shares sank -34.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.95% lower at present.
During the last 5 trading sessions, TXG fell by -4.84%, which changed the moving average for the period of 200-days by -70.68% in comparison to the 20-day moving average, which settled at $18.56. In addition, 10x Genomics Inc saw -72.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TXG starting from Saxonov Serge, who sale 6,749 shares at the price of $22.53 back on Aug 22 ’24. After this action, Saxonov Serge now owns 882,467 shares of 10x Genomics Inc, valued at $152,053 using the latest closing price.
Hindson Benjamin J., the of 10x Genomics Inc, sale 4,351 shares at $22.53 during a trade that took place back on Aug 22 ’24, which means that Hindson Benjamin J. is holding 345,704 shares at $98,027 based on the most recent closing price.
Stock Fundamentals for TXG
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.64 for the gross margin
The net margin for 10x Genomics Inc stands at -0.38. The total capital return value is set at -0.28. Equity return is now at value -31.61, with -24.99 for asset returns.
Based on 10x Genomics Inc (TXG), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -0.09. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -21049.09.
Currently, EBITDA for the company is -158.25 million with net debt to EBITDA at 1.49. When we switch over and look at the enterprise to sales, we see a ratio of 2.43. The receivables turnover for the company is 6.93for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.22.
Conclusion
In summary, 10x Genomics Inc (TXG) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
